*Since the 2003 launch of Somatuline® Autogel® (lanreotide) in Australia, Ipsen has an ongoing commitment to research and development for patients.2-4

Request for Somatuline Information

Book a training session

  • Rep email address from Veeva approved email only. Veeva email to pass: {{userEmailAddress}}
  • Veeva Account ID, passed via Veeva Approved email only.

References:

  1. Somatuline® Autogel® Approved Product Information.
  2. Adelman DT, et al. Med Devices (Auckl) 2012;5:107.
  3. Data on File, Ipsen.
  4. Australian Government Department of Health, The Pharmaceutical Benefits Scheme (PBS): Schedule of PBS Changes
    Dec 2018.http://www.pbs.gov.au/publication/schedule/2018/12/2018-12-01-general-soc.pdf (Accessed 10 July 2019)